Show simple item record

Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).

dc.contributor.author Cancer and Leukemia Group B
dc.contributor.author Christakis, NA
dc.contributor.author Earle, CC
dc.contributor.author Henderson, IC
dc.contributor.author Herndon, James Emmett II
dc.contributor.author Lamont, EB
dc.contributor.author Schilsky, RL
dc.contributor.author Weeks, JC
dc.coverage.spatial United States
dc.date.accessioned 2018-03-01T14:21:22Z
dc.date.available 2018-03-01T14:21:22Z
dc.date.issued 2006-09-20
dc.identifier https://www.ncbi.nlm.nih.gov/pubmed/16985253
dc.identifier 98/18/1335
dc.identifier.uri https://hdl.handle.net/10161/16103
dc.description.abstract To determine the accuracy with which Medicare claims data measure disease-free survival in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We merged gold-standard clinical trial data of 45 elderly patients with node-positive breast cancer who were treated on the Cancer and Leukemia Group B (CALGB) adjuvant breast trial 9344 with Centers for Medicare and Medicaid Services (CMS) data files and compared the results of a CMS-based algorithm with the CALGB disease-free survival information to determine sensitivity and specificity. For 5-year disease-free survival, the sensitivity of the CMS-based algorithm was 100% (95% confidence interval [CI] = 81% to 100%), the specificity was 97% (95% CI = 83% to 100%), and the area under the receiver operator curve was 98[corrected]% (95% CI = 95[corrected]% to 100%). For 2-year disease-free survival, the test characteristics were less favorable: sensitivity was 83% (95% CI = 36% to 100%), specificity was 95% (95% CI = 83% to 100%), and area under the receiver operator curve was 89[corrected]% (95% CI = 72[corrected]% to 100%).
dc.language eng
dc.relation.ispartof J Natl Cancer Inst
dc.relation.isversionof 10.1093/jnci/djj363
dc.subject Aged
dc.subject Algorithms
dc.subject Area Under Curve
dc.subject Breast Neoplasms
dc.subject Disease-Free Survival
dc.subject Female
dc.subject Humans
dc.subject Lymphatic Metastasis
dc.subject Medicaid
dc.subject Medicare
dc.subject Middle Aged
dc.subject Multicenter Studies as Topic
dc.subject Neoplasm Recurrence, Local
dc.subject ROC Curve
dc.subject Sensitivity and Specificity
dc.subject United States
dc.title Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
dc.type Journal article
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/16985253
pubs.begin-page 1335
pubs.end-page 1338
pubs.issue 18
pubs.organisational-group Basic Science Departments
pubs.organisational-group Biostatistics & Bioinformatics
pubs.organisational-group Duke
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group School of Medicine
pubs.publication-status Published
pubs.volume 98
dc.identifier.eissn 1460-2105


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record